Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 754-756

  Opal, Steven M ^a,c   Keith Jr , James C ^b   Palardy, John E ^a   Parejo, Nicolas ^a  

^a BROWN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 11; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG ACTIVITY; FEMALE; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; COLONY COUNT, MICROBIAL; CYTOKINES; FEMALE; INTERLEUKIN-11; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; LIVER; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034090826     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315247     Document Type: Article

References (15)

1. Tepler I, Elias L, Smith JW, et al. A randomized, placebo-controlled trial of recombinant interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-14.
2. Liu Q, Du XX, Schindel DT, et al. Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J Pediatr Surg 1996;31:1057-60.
3. Orazi A, Du XX, Yang ZX, Skashai M, Williams DA. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 1996;75:33-40.
4. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998;41:1388-97.
5. Trepicchio WL, Wang L, Bozza M, Dorner AJ. Interleukin-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J Immunol 1997;159:5661-9.
6. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-vs-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998;102:115-23.
7. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563-9.
8. Havell EA, Moldawer LL, Helfgott D, et al. Type I IL-1 receptor blockade exacerbates murine listeriosis. J Immunol 1992;148:1486-92.
9. Opal SM, Cross AS, Jhung JW, Palardy JE, Parejo N. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 1996;173:1415-21.
10. Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998;27:1497-507.
11. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PW. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob Agents Chemother 1999;43:1242-51.
12. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hygiene 1938;27:493-7.
13. Dorner AJ, Goldman SJ, Keith JC Jr. Interleukin-11: biological activity and clinical studies. Biodrugs 1997;8:418-29.
14. Opal SM, Jhung J, Keith JC Jr, Palardy JE, Parejo N, Schaub R. Human recombinant interleukin-11 in the treatment of immunocompromised animals with experimental Pseudomonas aeruginosa sepsis. J Infect Dis 1998;178:1205-8.
15. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with Crohn's disease. Gastroenterology 1999;117:58-64.